Jones Financial Companies Lllp Lowers Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Jones Financial Companies Lllp decreased its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 9.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,956 shares of the biopharmaceutical company’s stock after selling 730 shares during the period. Jones Financial Companies Lllp’s holdings in Royalty Pharma were worth $177,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in RPRX. Swedbank AB grew its stake in shares of Royalty Pharma by 10.3% during the fourth quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock valued at $310,308,000 after buying an additional 1,136,800 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after buying an additional 1,103,341 shares during the last quarter. Two Sigma Advisers LP grew its stake in shares of Royalty Pharma by 44.7% during the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after buying an additional 936,900 shares during the last quarter. Point72 Asset Management L.P. bought a new position in shares of Royalty Pharma during the third quarter valued at about $14,898,000. Finally, Geode Capital Management LLC grew its stake in shares of Royalty Pharma by 6.1% during the third quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock valued at $205,562,000 after buying an additional 417,490 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Up 0.3 %

NASDAQ RPRX opened at $32.77 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The stock has a market capitalization of $18.89 billion, a PE ratio of 22.60, a PEG ratio of 2.31 and a beta of 0.47. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.20. The business’s 50-day moving average is $31.58 and its 200 day moving average is $28.56.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Sell-side analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were issued a $0.22 dividend. The ex-dividend date of this dividend was Friday, February 21st. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a yield of 2.69%. Royalty Pharma’s dividend payout ratio (DPR) is 60.69%.

Wall Street Analysts Forecast Growth

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Royalty Pharma currently has an average rating of “Buy” and a consensus price target of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.